SGLT
SGLT (sodium-glucose linked transporter) uses the energy from the downhill sodium ion gradient created by the ATPase pump to transport glucose across the apical membrane against an uphill glucose gradient.
Products for SGLT
- Cat.No. Product Name Information
- GC19065 Bexagliflozin Bexagliflozin is a potent and selective SGLT2 inhibitor with IC50 value of 5.6 uM /2 nM in SGLT1 /SGLT2 respectively.
- GC13771 Canagliflozin SGLT2 inhibitor,potent and selective
- GC39178 Canagliflozin D4 Canagliflozin D4 is a deuterium labeled Canagliflozin.
- GC35603 Canagliflozin hemihydrate Canagliflozin hemihydrate (JNJ28431754 hemihydrate) is a selective SGLT2 inhibitor with IC50s of 2 nM, 3.7 nM, and 4.4 nM for mSGLT2, rSGLT2, and hSGLT2 in CHOK cells, respectively.
-
GC15530
Dapagliflozin
Dapagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, is a novel antidiabetic agent that is approved for the treatment of T2DM by based on its ability to inhibit SGLT2-mediated renal glucose reabsorption.
- GC35809 Dapagliflozin ((2S)-1,2-propanediol, hydrate) Dapagliflozin ((2S)-1,2-propanediol, hydrate) is the S-enantiomer of Dapagliflozin 1,2-propanediol, hydrate.
- GC16212 Empagliflozin (BI 10773) An SGLT2 inhibitor
- GC64266 Enavogliflozin Enavogliflozin (DWP-16001), an antidiabetic agent, is an orally active, best-in-class and selective sodium-glucose cotransporter-2 (SGLT-2) inhibitor.
- GC36004 Ertugliflozin L-pyroglutamic acid Ertugliflozin L-pyroglutamic acid (PF-04971729 L-pyroglutamic acid) is a potent, selective and orally active inhibitor of the sodium-dependent glucose cotransporter 2 (SGLT2), with an IC50 of 0.877 nM for h-SGLT2.
- GC16697 fluoro-Dapagliflozin selective sodium-glucose cotransporter (SGLT) inhibitor
- GC17190 galacto-Dapagliflozin potent inhibitor of human SGLT2
- GC16469 Ipragliflozin SGLT2 inhibitor
- GC36326 Ipragliflozin L-Proline Ipragliflozin L-Proline is a highly potent and selective SGLT2 inhibitor with an IC50 of 2.8 nM; little and NO potency for SGLT1/3/4/5/6.
- GC31366 Licogliflozin (LIK066) Licogliflozin (LIK066) is a sodium glucose cotransporter (SGLT1 and SGLT2) inhibitor.
- GC15088 LX-4211 An SGLT inhibitor
- GC36498 LX2761 LX2761 is chemically stable and potent inhibitor against sodium-dependent glucose cotransporter 1 (SGLT1) and SGLT2 in vitro with IC50s of 2.2 nM and 2.7nM for hSGLT1 and hSGLT2, but displays specific SGLT1 inhibition in the gastrointestinal (GI) tract.
- GC60249 Mizagliflozin Mizagliflozin (DSP-3235 free base) is a potent, orally active and selective SGLT1 inhibitor, with a Ki of 27 nM for human SGLT1.
- GC16012 PF-04971729 An SGLT2 inhibitor
- GC17976 Phloretin A natural inhibitor of various transporters
- GN10029 Phloridzin
- GC31461 Tofogliflozin (CSG452) Tofogliflozin (CSG452)(CSG-452) is a potent and highly specific sodium/glucose cotransporter 2(SGLT2) inhibitor with Ki values of 2.9, 14.9, and 6.4 nM for human, rat, and mouse SGLT2.
- GC31377 Tofogliflozin hydrate (CSG-452 hydrate) Tofogliflozin hydrate (CSG-452 hydrate) is a potent and highly specific sodium/glucose cotransporter 2 (SGLT2) inhibitor with an IC50 of 2.9 nM and Ki values of 2.9 nM, 14.9 nM, and 6.4 nM for human, rat, and mouse SGLT2.
- GC41374 Trilobatin Trilobatin is a dihydrochalcone glucoside and derivative of phloretin that has been found in Rooibos (A.
-
GC31593
Velagliflozin
Velagliflozin is an orally available sodium-glucose cotransporter 2 (SGLT2) inhibitor, with anti-diabetic activity.
-
GC70113
Velagliflozin proline
Velagliflozin proline is an orally administered sodium-glucose co-transporter 2 (SGLT2) inhibitor with anti-diabetic activity. Specifically, Velagliflozin proline reduces renal glucose reabsorption, promotes glucosuria, and thereby lowers blood glucose and insulin concentrations.